查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971247

抗体发现市场分析及预测（至2035年）：按类型、产品、服务、技术、应用、最终用户、流程、模式、阶段和解决方案划分

Antibody Discovery Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Mode, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5个工作天内

价格
简介目录

抗体发现市场预计将从2024年的28亿美元成长到2034年的104亿美元，复合年增长率约为14%。抗体发现市场涵盖用于治疗、诊断和研究应用的抗体的鑑定和开发。噬菌体展示、融合瘤和次世代定序等先进技术正在广泛应用。慢性病盛行率的上升、对标靶治疗的需求以及单株抗体和双特异性抗体的创新预计将带来巨大的成长机会。

受生物技术进步和标靶治疗需求成长的推动，抗体发现市场持续强劲扩张。单株抗体凭藉其特异性和治疗潜力，表现优异。双特异性抗体因其能够同时靶向多个标靶而成为第二大细分市场。在发现阶段，噬菌体展示技术因其能够快速且有效率地筛选抗体而备受关注。融合瘤技术因其可靠性和成本效益而仍然很重要。由于人源化抗体具有免疫抗原性降低和临床应用疗效提高的优势，市场对其需求不断增长。此外，人工智慧（AI）和机器学习在抗体发现过程中的应用日益广泛，优化了候选抗体的选择，并缩短了研发週期。製药公司与研究机构之间的合作正在促进创新，并拓展产品线。研发投入的增加以及慢性疾病盛行率的上升对新型治疗方案的需求，进一步推动了市场成长。

市场区隔
类型 单株抗体、多株抗体、双特异性抗体、抗体片段
产品 试剂、试剂盒、仪器、软体
服务 抗体筛检、人源化抗体、抗体工程、抗体生产
科技 噬菌体展示技术、融合瘤技术、基因改造动物技术、B细胞分选
目的 肿瘤学、感染疾病、自体免疫疾病、心血管疾病、神经病学
最终用户 製药公司、生技公司、学术研究机构、受託研究机构
过程 药物发现、开发、生产和验证
模式 体内试验、试管内试验、模拟试验
步 先导化合物开发、先导药物最适化、临床前研究、临床研究
解决方案 客製化抗体服务，抗体目录

市场概况：

抗体发现市场是一个充满活力的市场环境，市场占有率受策略定价模式和创新产品线推出的显着影响。各公司日益专注于提供满足特定研究需求的客製化解决方案，从而增强其竞争优势。在生物技术进步和标靶治疗需求不断增长的推动下，新产品上市数量激增。旨在加速产品开发和市场渗透的策略联盟和伙伴关係进一步推动了这一趋势。抗体发现市场的竞争异常激烈，主要企业力求在技术上取得优势并占据市场主导地位。与行业领导者的对标分析表明，创新和效率是其关注的重点。监管影响，尤其是在北美和欧洲，对市场动态的塑造起着至关重要的作用，严格的指导方针影响产品开发和核准流程。儘管面临高昂的开发成本和监管壁垒等挑战，但在研发投入增加和强大的抗体疗法产品线的支持下，市场仍呈现出成长动能。

主要趋势和驱动因素：

受基因工程和生物资讯学进步的推动，抗体发现市场正经历强劲成长。一个关键趋势是将人工智慧（AI）融入抗体设计，从而提高发现过程的准确性和速度。这项技术进步使得开发高特异性和高疗效的治疗性抗体成为可能。此外，单株抗体作为包括癌症和自体免疫疾病在内的多种疾病的首选治疗方法，其出现也推动了市场需求。新型抗体疗法的监管核准不断增加，进一步促进了市场扩张。人们对个人化医疗日益增长的兴趣也是一个重要的驱动因素，因为抗体可以根据每位患者的个别需求进行客製化。此外，生物技术公司与学术机构之间的合作正在促进创新并加速研究进程。随着全球对改善医疗保健成果的关注度不断提高，抗体发现市场预计将继续保持成长动能。新兴市场由于医疗基础设施的快速发展和对先进疗法需求的不断增长，蕴藏着许多机会。

压制与挑战：

抗体发现市场面临许多重大限制和挑战。其中一项主要挑战是先进技术和製程的高成本。这种经济负担限制了中小企业和研究机构进入市场，阻碍了创新和竞争。此外，市场也面临专业人才短缺的问题。开发新型抗体需要生物资讯学、分子生物学及相关领域的专业知识。此类人才的匮乏阻碍了发展和创新。监管障碍也是一项重大挑战。新型抗体疗法的严格核准流程导致市场准入延迟和成本增加。企业必须应对复杂的监管环境，这在时间和金钱方面都造成了沉重的负担。此外，科技的快速变化也影响市场状况。跟上最新进展需要持续的投资和调整，这对许多企业来说都是一项挑战。最后，智慧财产权问题也构成障碍。专利纠纷和授权协议的复杂性会阻碍合作和创新，从而可能抑制市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 多株抗体
    • 双特异性抗体
    • 抗体片段
  • 市场规模及预测：依产品划分
    • 试剂
    • 成套工具
    • 装置
    • 软体
  • 市场规模及预测：依服务划分
    • 抗体筛检
    • 人源化抗体
    • 抗体工程
    • 抗体产生
  • 市场规模及预测：依技术划分
    • 噬菌体展示
    • 融合瘤技术
    • 基因改造动物技术
    • B细胞分级分离
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 感染疾病
    • 自体免疫疾病
    • 心血管疾病
    • 神经病学
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 学术研究机构
    • 受託研究机构
  • 市场规模及预测：依製程划分
    • 药物发现
    • 发展
    • 生产
    • 检验
  • 市场规模及预测：按模式
    • In vivo
    • 体外
    • In Silico
  • 市场规模及预测：依阶段划分
    • 潜在客户开发
    • 先导药物最适化
    • 临床前阶段
    • 临床
  • 市场规模及预测：按解决方案划分
    • 客製化抗体服务
    • 目录抗体

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Abcam
  • GenScript Biotech
  • Sino Biological
  • Creative Biolabs
  • Absolute Antibody
  • Adimab
  • Antibody Solutions
  • Apexigen
  • ImmunoPrecise Antibodies
  • Ligand Pharmaceuticals
  • MorphoSys
  • ProMab Biotechnologies
  • Bio-Rad Laboratories
  • Crown Bioscience
  • Innovent Biologics

第九章 关于我们

简介目录
Product Code: GIS33628

Antibody Discovery Market is anticipated to expand from $2.8 billion in 2024 to $10.4 billion by 2034, growing at a CAGR of approximately 14%. The Antibody Discovery Market encompasses the identification and development of antibodies for therapeutic, diagnostic, and research applications. It involves advanced technologies such as phage display, hybridoma, and next-generation sequencing. The market is driven by the increasing prevalence of chronic diseases, demand for targeted therapies, and innovations in monoclonal and bispecific antibodies, promising significant growth opportunities.

The Antibody Discovery Market is experiencing robust expansion, driven by advancements in biotechnology and rising demand for targeted therapies. The monoclonal antibodies segment leads in performance, owing to their specificity and therapeutic potential. Bispecific antibodies are emerging as the second-highest performing sub-segment, reflecting their ability to engage multiple targets simultaneously. In the discovery phase, phage display technology stands out, offering rapid and efficient antibody selection. Hybridoma technology remains significant, valued for its established reliability and cost-effectiveness. The demand for humanized antibodies is increasing, driven by their reduced immunogenicity and enhanced efficacy in clinical applications. Moreover, the integration of artificial intelligence and machine learning in antibody discovery processes is gaining momentum, optimizing candidate selection and accelerating timelines. Partnerships between pharmaceutical companies and research institutions are fostering innovation and expanding pipeline portfolios. The market's growth is further supported by increasing investments in R&D and the rising prevalence of chronic diseases, necessitating novel therapeutic solutions.

Market Segmentation
TypeMonoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody Fragments
ProductReagents, Kits, Instruments, Software
ServicesAntibody Screening, Antibody Humanization, Antibody Engineering, Antibody Production
TechnologyPhage Display, Hybridoma Technology, Transgenic Animal Technology, B Cell Sorting
ApplicationOncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Neurology
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations
ProcessDiscovery, Development, Production, Validation
ModeIn Vivo, In Vitro, In Silico
StageLead Generation, Lead Optimization, Preclinical, Clinical
SolutionsCustom Antibody Services, Catalog Antibodies

Market Snapshot:

The Antibody Discovery Market is characterized by a dynamic landscape where market share is largely influenced by strategic pricing models and the introduction of innovative product lines. Companies are increasingly focusing on customized solutions to cater to specific research needs, which enhances their competitive positioning. The market is witnessing a surge in new product launches, driven by advancements in biotechnology and increased demand for targeted therapies. This trend is further supported by strategic collaborations and partnerships that aim to accelerate product development and market penetration. Competition in the Antibody Discovery Market is intense, with key players striving for technological superiority and market dominance. Benchmarking against industry leaders reveals a focus on innovation and efficiency. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics, with stringent guidelines impacting product development and approval processes. The market is poised for growth, fueled by increasing R&D investments and a robust pipeline of antibody therapeutics, despite challenges such as high development costs and regulatory hurdles.

Geographical Overview:

The antibody discovery market is witnessing remarkable growth across various regions, each characterized by unique opportunities. North America remains a dominant force, driven by advanced biotechnological research and substantial funding for antibody development. The presence of leading pharmaceutical companies further propels the market, fostering innovation and collaboration. Europe follows closely, with robust government support and a strong focus on research and development in antibody technologies. The region's emphasis on personalized medicine enhances its market potential. In Asia Pacific, rapid advancements in biotechnology and increasing healthcare investments are fueling market expansion. Countries like China and India are emerging as significant contributors, thanks to their growing biopharmaceutical industries. Latin America and the Middle East & Africa are also gaining traction, albeit at a slower pace. In Latin America, increasing investments in healthcare infrastructure and a rising focus on innovative therapies are driving growth. Meanwhile, the Middle East & Africa are recognizing the potential of antibody discovery in addressing regional healthcare challenges.

Key Trends and Drivers:

The antibody discovery market is experiencing robust growth, propelled by advancements in genetic engineering and bioinformatics. A key trend is the integration of artificial intelligence in antibody design, which enhances the precision and speed of discovery processes. This technological evolution is enabling the development of highly specific and effective therapeutic antibodies. Moreover, the rise of monoclonal antibodies as a preferred treatment for various diseases, including cancer and autoimmune disorders, is driving demand. Regulatory approvals of novel antibody therapies are increasing, further encouraging market expansion. The burgeoning interest in personalized medicine is also a significant driver, as antibodies can be tailored to individual patient needs. Additionally, collaborations between biotechnology firms and academic institutions are fostering innovation and accelerating research timelines. As the global focus on improving healthcare outcomes intensifies, the antibody discovery market is poised for sustained growth. Opportunities abound in emerging markets, where healthcare infrastructure is rapidly developing, and demand for advanced therapeutics is rising.

Restraints and Challenges:

The antibody discovery market encounters several significant restraints and challenges. A primary challenge is the high cost associated with advanced technologies and processes. This financial burden restricts smaller companies and research institutions from entering the market, limiting innovation and competition. Furthermore, the market suffers from a shortage of skilled professionals. Expertise in bioinformatics, molecular biology, and related fields is crucial for the development of novel antibodies. The lack of such talent hampers progress and innovation. Regulatory hurdles also pose a significant challenge. Stringent approval processes for new antibody therapies can delay market entry and increase costs. Companies must navigate complex regulatory landscapes, which can be both time-consuming and expensive. Moreover, the market is affected by the rapid pace of technological change. Keeping up with the latest advancements requires constant investment and adaptation, which can be burdensome for many organizations. Lastly, intellectual property issues create barriers. Patent disputes and the complexity of licensing agreements can stifle collaboration and innovation, hindering market growth.

Key Players:

Abcam, GenScript Biotech, Sino Biological, Creative Biolabs, Absolute Antibody, Adimab, Antibody Solutions, Apexigen, ImmunoPrecise Antibodies, Ligand Pharmaceuticals, MorphoSys, ProMab Biotechnologies, Bio-Rad Laboratories, Crown Bioscience, Innovent Biologics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Polyclonal Antibodies
    • 4.1.3 Bispecific Antibodies
    • 4.1.4 Antibody Fragments
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Kits
    • 4.2.3 Instruments
    • 4.2.4 Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Antibody Screening
    • 4.3.2 Antibody Humanization
    • 4.3.3 Antibody Engineering
    • 4.3.4 Antibody Production
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Phage Display
    • 4.4.2 Hybridoma Technology
    • 4.4.3 Transgenic Animal Technology
    • 4.4.4 B Cell Sorting
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Autoimmune Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Neurology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Discovery
    • 4.7.2 Development
    • 4.7.3 Production
    • 4.7.4 Validation
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 In Vivo
    • 4.8.2 In Vitro
    • 4.8.3 In Silico
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Lead Generation
    • 4.9.2 Lead Optimization
    • 4.9.3 Preclinical
    • 4.9.4 Clinical
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Custom Antibody Services
    • 4.10.2 Catalog Antibodies

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Abcam
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 GenScript Biotech
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sino Biological
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Creative Biolabs
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Absolute Antibody
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Adimab
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Antibody Solutions
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Apexigen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 ImmunoPrecise Antibodies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Ligand Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 MorphoSys
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ProMab Biotechnologies
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio-Rad Laboratories
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Crown Bioscience
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Innovent Biologics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us